KRYSTAL-1: promising results forKRAS-G12C inhibitor in colorectal cancer

External site

By following this link, you are leaving Medically and entering a website that is not owned or controlled by Roche. Roche does not take any responsibility for access to or use of this website, nor for any content therein.

Leave site

Sep 19 / Springer Healthcare

KRYSTAL-1: promising results forKRAS-G12C inhibitor in colorectal cancer

Oncology Gastrointestinal Cancer ESMO-2021

Description

Independent commentator Eric Van Cutsem discusses the results for adagrasib given as monotherapy or combined with cetuximab to colorectal cancer patients harbouring a KRAS-G12C mutation

This website is intended for healthcare professionals outside the United Kingdom (UK) and Australia. Registration status and prescribing information of medicinal products may differ between countries. Please refer to local product information for any medicinal products mentioned on this website.